Development of adjuvant-active nonionic block copolymers

被引:62
作者
Newman, MJ
Balusubramanian, M
Todd, CW
机构
[1] Vaxcel Inc, Norcross, GA 30092 USA
[2] CytRx Corp, Norcross, GA 30092 USA
关键词
adjuvant; nonionic block copolymer; parenteral vaccination; oral vaccination; emulsion; cellular immunity; antibody responses;
D O I
10.1016/S0169-409X(98)00011-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonionic block copolymers are surfactants synthesized using propylene oxide (PQ) and ethylene oxide (EO) which are organized as 'blocks' of polyoxyethylene (POE) and polyoxylpropylene (POP). These copolymers can be designed and synthesized using variable amounts of the PO and EO and with differential arrangement of the POP and POE blocks so that individual products have unique physicochemical properties. The copolymers that have been most thoroughly evaluated in vaccine research are linear with the polymer blocks organized as POE-POP-POE. Low molecular weight (MW) copolymers, 3-6 kDa, of this type have been used in oil-based emulsion formulations, whereas high-MW copolymers, > 9 kDa, can be used in aqueous formulations. The adjuvant activity of nonionic block copolymers is influenced greatly by the size of the POP core block. As the size of this block is increased so is the adjuvant activity of the copolymer; peak activity is achieved using copolymers with POP cores that are 12-15 kDa. However, adjuvant activity is also affected by the amount of POE with low concentrations, 5-10%, being optimal. The type of-immune responses produced is also influenced by the POE content. Copolymers with 10% POE preferentially augment Type 2 helper T-lymphocyte responses which support antibody responses, including mucosal antibody responses. Copolymers with < 10% POE augment both Type 1 and Type 2 helper T-lymphocyte responses, which support a broader range of antibody responses and cellular immune responses. This property may allow for vaccines to be 'customized' by using adjuvant-active nonionic block copolymers that will augment the most appropriate types of immune responses. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:199 / 223
页数:25
相关论文
共 67 条
[1]  
ALLISON AC, 1992, ADV EXP MED BIOL, V327, P133
[2]   AN ADJUVANT FORMULATION THAT SELECTIVELY ELICITS THE FORMATION OF ANTIBODIES OF PROTECTIVE ISOTYPES AND OF CELL-MEDIATED-IMMUNITY [J].
ALLISON, AC ;
BYARS, NE .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (02) :157-168
[3]   SYNTEX ADJUVANT FORMULATION [J].
ALLISON, AC ;
BYARS, NE .
RESEARCH IN IMMUNOLOGY, 1992, 143 (05) :519-525
[4]   A COMPARISON OF COMMERCIALLY AVAILABLE ADJUVANTS FOR USE IN RESEARCH [J].
BENNETT, B ;
CHECK, IJ ;
OLSEN, MR ;
HUNTER, RL .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 153 (1-2) :31-40
[5]   VACCINATING GUINEA-PIGS WITH RECOMBINANT GLYCOPROTEIN-D OF HERPES-SIMPLEX VIRUS IN AN EFFICACIOUS ADJUVANT FORMULATION ELICITS PROTECTION AGAINST VAGINAL INFECTION [J].
BYARS, NE ;
FRASERSMITH, EB ;
PECYK, RA ;
WELCH, M ;
NAKANO, G ;
BURKE, RL ;
HAYWARD, AR ;
ALLISON, AC .
VACCINE, 1994, 12 (03) :200-209
[6]   IDENTIFICATION OF POTENTIAL CTL EPITOPES OF TUMOR-ASSOCIATED ANTIGEN MAGE-1 FOR 5 COMMON HLA-A ALLELES [J].
CELIS, E ;
FIKES, J ;
WENTWORTH, P ;
SIDNEY, J ;
SOUTHWOOD, S ;
MAEWAL, A ;
DELGUERCIO, MF ;
SETTE, A ;
LIVINGSTON, B .
MOLECULAR IMMUNOLOGY, 1994, 31 (18) :1423-1430
[7]  
CHEN YH, 1995, J IMMUNOL, V155, P910
[8]   FREUND COMPLETE ADJUVANT - AN EFFECTIVE BUT DISAGREEABLE FORMULA [J].
CLAASSEN, E ;
DELEEUW, W ;
DEGREEVE, P ;
HENDRIKSEN, C ;
BOERSMA, W .
RESEARCH IN IMMUNOLOGY, 1992, 143 (05) :478-483
[9]  
COLLINS DS, 1992, J IMMUNOL, V148, P3336
[10]  
COOPER PD, 1993, ACTIVATORS INHIBITOR, P69